Recursion (NASDAQ: RXRX), a cutting-edge clinical-stage TechBio company, has announced the successful dosing of the first patient in its Phase 1/2 DAHLIA clinical trial of REC-1245, a novel RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma.
AI-Driven Discovery Accelerates REC-1245 Development
Using AI-powered biological maps, Recursion identified the crucial role of RBM39 in regulating CDK12 activity. By targeting RBM39, REC-1245 offers a promising therapeutic strategy for patients with biomarker-enriched cancers. Preclinical studies show that RBM39 degradation disrupts RNA splicing, impairing DNA Damage Response (DDR) and cell cycle checkpoints, critical mechanisms in cancer progression.
Expert Insights: Advancing Precision Cancer Treatment
“The rise of personalized treatments in oncology provides new options for patients. We are thrilled to collaborate with Recursion on the DAHLIA trial, advancing cancer treatment science.”
— Dr. McKean, Clinical Investigator at START Mountain Region, Salt Lake City, UT
“Dosing the first patient in the DAHLIA trial is a key milestone for Recursion. REC-1245 could be a breakthrough for patients with biomarker-enriched cancers, showcasing our ability to rapidly translate novel insights into clinical programs.”
— Najat Khan, PhD, Chief R&D Officer & Chief Commercial Officer, Recursion
Overview of the DAHLIA Clinical Trial
The DAHLIA trial is a Phase 1/2 open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and early efficacy of REC-1245. The trial aims to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). REC-1245 is tested as both a standalone therapy and in combination with DDR inhibitors, checkpoint inhibitors, and chemotherapy.
Target Patient Population
Recursion estimates that over 100,000 patients in the US and EU5 with biomarker-enriched solid tumors and lymphoma could benefit from REC-1245.
About REC-1245
REC-1245 is an RBM39-targeting molecular glue, which promotes the degradation of RBM39 via E3 ligase adaptor DCAF15. This mechanism disrupts critical pathways like RNA splicing, cell cycle checkpoints, and DDR, including CDK12. Developed using Recursion’s AI-driven platform, REC-1245 offers a novel approach to targeting cancer-driving pathways.
About Recursion
Recursion (NASDAQ: RXRX) is a pioneering clinical-stage TechBio company dedicated to transforming drug discovery by decoding biological data. At its core, Recursion operates the Recursion OS platform, which enables vast data expansion and analysis. Through advanced machine learning and massive experimental scale, Recursion is integrating technology, biology, and patient-centric data to redefine the future of medicine.
By
